

# Stephen D Smith

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/169615/publications.pdf>

Version: 2024-02-01

41  
papers

1,159  
citations

516710

16  
h-index

395702

33  
g-index

42  
all docs

42  
docs citations

42  
times ranked

1727  
citing authors

#	ARTICLE	IF	CITATIONS
1	Megadose 90Y-ibritumomab tiuxetan prior to allogeneic transplantation is effective for aggressive large B-cell lymphoma. <i>Blood Advances</i> , 2022, 6, 37-45.	5.2	3
2	Management of relapsed or refractory large B-cell lymphoma in patients ineligible for CAR-T cell therapy. <i>Expert Review of Hematology</i> , 2022, 15, 215-232.	2.2	2
3	Polatuzumab vedotin with dose-adjusted etoposide, cyclophosphamide, doxorubicin, and rituximab (Pola-DA-EPCH-R) for upfront treatment of aggressive B-cell non-Hodgkin lymphomas.. <i>Journal of Clinical Oncology</i> , 2022, 40, 7546-7546.	1.6	1
4	Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers. <i>Blood</i> , 2021, 137, 374-386.	1.4	59
5	Yttrium-90 Anti-CD45 Immunotherapy Followed by Autologous Hematopoietic Cell Transplantation for Relapsed or Refractory Lymphoma. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 57.e1-57.e8.	1.2	7
6	Outcomes of Burkitt lymphoma with central nervous system involvement: evidence from a large multicenter cohort study. <i>Haematologica</i> , 2021, 106, 1932-1942.	3.5	21
7	Polatuzumab Vedotin for Relapsed/Refractory Aggressive B-cell Lymphoma: A Multicenter Post-marketing Analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 170-175.	0.4	17
8	Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma. <i>Blood Advances</i> , 2021, 5, 1648-1659.	5.2	28
9	Burkitt Lymphoma International Prognostic Index. <i>Journal of Clinical Oncology</i> , 2021, 39, 1129-1138.	1.6	37
10	Umbralisib: Walking the Tightrope of PI3K Inhibition in Indolent NHL. <i>Journal of Clinical Oncology</i> , 2021, 39, 1671-1673.	1.6	0
11	HIV-associated Burkitt lymphoma: outcomes from a US-UK collaborative analysis. <i>Blood Advances</i> , 2021, 5, 2852-2862.	5.2	24
12	Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 study. <i>Lancet Haematology</i> , 2021, 8, e562-e571.	4.6	28
13	Clinicopathologic Findings in Patients With Initial Diagnosis of Extranodal Marginal Zone B-Cell Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT) in Colorectal Mucosa. <i>American Journal of Clinical Pathology</i> , 2021, , .	0.7	1
14	High-Grade B-Cell Lymphoma, Not Otherwise Specified (HGBL, NOS): Characteristics, Treatment, and Outcomes from 17 Academic US Centers. <i>Blood</i> , 2021, 138, 455-455.	1.4	4
15	Concurrent Pembrolizumab with AVD for Untreated Classical Hodgkin Lymphoma. <i>Blood</i> , 2021, 138, 233-233.	1.4	6
16	Safety and Efficacy of Third Generation CD20 Targeted CAR-T (MB-106) for Treatment of Relapsed/Refractory B-NHL and CLL. <i>Blood</i> , 2021, 138, 3872-3872.	1.4	7
17	Impact of Double- or Triple-Hit Pathology on Rates and Durability of Radiation Therapy Response Among Patients With Relapsed or Refractory Large B-Cell Lymphoma. <i>Practical Radiation Oncology</i> , 2020, 10, 44-52.	2.1	10
18	Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity. <i>Journal of Clinical Oncology</i> , 2020, 38, 3095-3106.	1.6	216

#	ARTICLE	IF	CITATIONS
19	Selinexor for relapsed or refractory diffuse large B-cell lymphoma: examining the artifact. <i>Lancet Haematology</i> , 2020, 7, e707.	4.6	2
20	Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis. <i>Blood Advances</i> , 2020, 4, 5773-5784.	5.2	67
21	Addressing the conundrum of male predominance in mantle cell lymphoma using androgen receptor blockade. <i>British Journal of Haematology</i> , 2020, 190, e332-e335.	2.5	2
22	Pembrolizumab with R-CHOP in previously untreated diffuse large B-cell lymphoma: potential for biomarker driven therapy. <i>British Journal of Haematology</i> , 2020, 189, 1119-1126.	2.5	69
23	Eligibility for CAR T-cell therapy: An analysis of selection criteria and survival outcomes in chemorefractory DLBCL. <i>American Journal of Hematology</i> , 2019, 94, E117-E116.	4.1	19
24	Outcomes of patients with large B-cell lymphomas and progressive disease following CD19-specific CAR T-cell therapy. <i>American Journal of Hematology</i> , 2019, 94, E209-E213.	4.1	92
25	Outcomes of Patients With Therapy-Related MDS After Chemoimmunotherapy for Chronic Lymphocytic Leukemia Compared With Patients With De Novo MDS: A Single-Institution Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 390-395.	0.4	6
26	A pilot study of weekly brentuximab vedotin in patients with <math>CD30+</math> malignancies resistant to brentuximab vedotin every 3 weeks. <i>British Journal of Haematology</i> , 2019, 186, 159-162.	2.5	3
27	Modified VR-CAP, Alternating With Rituximab and High-dose Cytarabine: An Effective Pre-transplant Induction Regimen for Mantle Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 48-52.	0.4	1
28	Gemcitabine: End of a Chemotherapy's Era?. <i>Acta Haematologica</i> , 2019, 141, 91-92.	1.4	3
29	Outcomes of Patients with Newly-Diagnosed Burkitt Lymphoma (BL) and Central Nervous System (CNS) Involvement Treated in the Modern Era: A Multi-Institutional Real-World Analysis. <i>Blood</i> , 2019, 134, 402-402.	1.4	9
30	A phase I trial of bortezomib in combination with everolimus for treatment of relapsed/refractory non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2018, 59, 690-694.	1.3	4
31	Total Body Irradiation Is Safe and Similarly Effective as Chemotherapy-Only Conditioning in Autologous Stem Cell Transplantation for Mantle Cell Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 282-287.	2.0	8
32	First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL. <i>Oncotarget</i> , 2018, 9, 13023-13035.	1.8	70
33	Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma. <i>Blood</i> , 2017, 129, 2224-2232.	1.4	243
34	Pegylated GCSF Can Be Used With First-Line da-EPOCH-R Without Compromising Dose Intensity, Safety, or Efficacy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, e87-e90.	0.4	3
35	A multi-institutional outcomes analysis of patients with relapsed or refractory DLBCL treated with ibrutinib. <i>Blood</i> , 2017, 130, 1676-1679.	1.4	26
36	Real World Utilization and Practice Patterns of Dose-Adjusted EPOCH for Aggressive B-Cell Lymphomas 2005-2015: Impact of Growth Factor Choice and Resultant Achieved Dose Level. <i>Blood</i> , 2016, 128, 3577-3577.	1.4	0

#	ARTICLE	IF	CITATIONS
37	FDG PET-CT in follicular lymphoma: a case-based evidence review. <i>Blood</i> , 2015, 125, 1078-1082.	1.4	19
38	Brentuximab vedotin administered to platinum-refractory, transplant-naïve Hodgkin lymphoma patients can increase the proportion achieving FDG PET negative status. <i>Hematological Oncology</i> , 2015, 33, 187-191.	1.7	10
39	Diffuse large B-cell lymphoma in adults aged 75 years and older: a single institution analysis of cause-specific survival and prognostic factors. <i>Therapeutic Advances in Hematology</i> , 2013, 4, 349-353.	2.5	14
40	Interpretation of pre- versus postimplant TRUS images. <i>Medical Physics</i> , 2003, 30, 920-924.	3.0	16
41	Predictors of cytopenias after treatment with axicabtagene ciloleucel in patients with large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 0, , 1-5.	1.3	0